Lineage Cell Therapeutics, Inc.
LCTX
$1.68
$0.074.35%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -881.58% | -428.89% | 36.73% | 31.46% | 57.33% |
| Total Depreciation and Amortization | 26.24% | 20.42% | -6.29% | -13.71% | -19.89% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3,269.19% | 1,648.77% | -142.50% | -7.81% | -59.82% |
| Change in Net Operating Assets | 57.62% | -112.27% | 71.15% | -145.88% | -2,570.50% |
| Cash from Operations | 37.52% | -7.01% | 15.51% | -5.43% | -14.89% |
| Capital Expenditure | 89.29% | 72.00% | -155.26% | -301.10% | 19.42% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.00% | 100.00% | -- | -69.49% | 76.91% |
| Cash from Investing | -100.31% | 99.84% | 5,107.89% | -72.95% | 83.22% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -23.08% | 0.00% | -7.69% | -7.69% | -8.33% |
| Issuance of Common Stock | 20,720.00% | -- | -62.32% | -- | -98.82% |
| Repurchase of Common Stock | -- | -- | 34.78% | 100.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -129.15% | -- |
| Cash from Financing | 61,233.33% | -392.38% | -64.03% | 167,284.62% | -100.37% |
| Foreign Exchange rate Adjustments | -110.53% | 432.95% | -4.29% | -91.13% | 111.18% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3.54% | 60.10% | -75.55% | 352.10% | 23.86% |